Cyclosporine, Modified · oral capsule
Misc.
OFF-LABELNot in the FDA label for this product
Non-infectious intermediate or posterior uveitis
Oral, dosed to effect and to renal tolerance; the trial used doses high enough to raise creatinine and blood pressure
RCT · n=56 · only 46% each
A randomized double-masked trial compared cyclosporine with prednisolone in 56 patients with bilateral sight-threatening non-infectious intermediate or posterior uveitis. Visual acuity or vitreous haze improved in only 13 of 28 patients (46%) in each arm, and macular edema resolved in 7 of 15 on cyclosporine against 10 of 16 on prednisolone (p=0.376). Twenty-eight patients per arm cannot exclude a real difference, so this is a failure to detect one rather than a demonstration that the two are equal, and the authors' own word is that only 46% improved: two mediocre options, not two good ones. Patients who failed both drugs alone improved on the combination. The notable adverse effects were rises in serum creatinine and hypertension. Formulation caveat, which comes from the dates rather than from the paper: this trial published in 1991 and the Neoral microemulsion reached the market in 1995, so it necessarily used the original oil-based formulation. The two are not interchangeable without blood-level monitoring, and Neoral gives higher exposure per milligram, so neither the response rate nor the creatinine and blood-pressure signal transfers dose for dose.
Non-infectious ocular inflammation, as a corticosteroid-sparing agent
151 to 250 mg daily in adults; the cohort found lower doses less successful and higher doses no better
Cohort · n=373 · 52% at 1 yr
The Systemic Immunosuppressive Therapy for Eye Diseases cohort followed 373 patients starting cyclosporine as their single non-corticosteroid agent. Sustained complete control of inflammation was reached by 33.4% at 6 months and 51.9% at 1 year, and corticosteroid-sparing success, meaning controlled inflammation on prednisone of 10 mg a day or less, by 22.1% and 36.1%. Toxicity ended treatment within a year in 10.7%, and patients over 55 were more than three times as likely to stop for toxicity as those aged 18 to 39, so an alternative agent may suit older patients better. The authors describe the drug as modestly effective. The cohort spans 1979 to 2007 and so straddles both the oil-based and microemulsion formulations.
Contraindications
- Neoral is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation
- Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies
- Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies
- Concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy in psoriasis patients
25 mg capsules (30), 100 mg capsules (30), 100 mg/mL oral solution (50 mL)
Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Its effectiveness results from specific and reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited, and the T-helper cell is the main target, although the T-suppressor cell may also be suppressed. Cyclosporine also inhibits lymphokine production and release, including interleukin-2.
Warnings & Precautions
- Infection and neoplasia: Neoral, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. Only physicians experienced in management of systemic immunosuppressive therapy for the indicated disease should prescribe Neoral, and patients should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.
- Not bioequivalent: Neoral and Sandimmune are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with Neoral than with Sandimmune. If a patient who is receiving exceptionally high doses of Sandimmune is converted to Neoral, particular caution should be exercised.
- Underdosing: Conversion from Neoral to Sandimmune using a 1:1 ratio (mg/kg/day) may result in lower cyclosporine blood concentrations and should be made with increased monitoring to avoid the potential of underdosing.
- Toxicity due to high concentrations: Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking Neoral to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.
- Nephrotoxicity: Cyclosporine can cause nephrotoxicity, and the risk increases with increasing dose and duration of therapy. Renal dysfunction, including structural kidney damage, is a potential consequence, so renal function must be monitored during therapy. Care should be taken in using cyclosporine with nephrotoxic drugs. Elderly patients should be monitored with particular care.
- Nephrotoxicity in transplant patients: In renal transplant patients, elevated serum creatinine and BUN do not necessarily indicate rejection, and each patient must be fully evaluated before dosage adjustment is initiated. Up to 20% of patients may have simultaneous nephrotoxicity and rejection.
- Hepatotoxicity: Cases of hepatotoxicity and liver injury, including cholestasis, jaundice, hepatitis, and liver failure, have been reported in patients treated with cyclosporine. In some cases, mainly in transplant patients, fatal outcomes have been reported. The risk increases with increasing doses of cyclosporine.
- Hypertension: Cyclosporine, in recommended dosages, can cause systemic hypertension, which may persist. In transplant recipients, antihypertensive therapy may be required, but potassium-sparing diuretics should not be used because cyclosporine may cause hyperkalemia. Calcium antagonists can be effective in treating cyclosporine-associated hypertension, but they can interfere with cyclosporine metabolism.
- Thrombotic microangiopathy: Occasionally patients have developed a syndrome of thrombocytopenia and microangiopathic hemolytic anemia which may result in graft failure.
- Hyperkalemia: Significant hyperkalemia (sometimes associated with hyperchloremic metabolic acidosis) and hyperuricemia have been seen occasionally in individual patients.
- Malignancies: As with other immunosuppressants, patients receiving cyclosporine are at increased risk for development of lymphomas and other malignancies, particularly those of the skin, and some malignancies may be fatal. The increased risk appears related to the intensity and duration of immunosuppression. Patients should be warned to avoid excess ultraviolet light exposure, and rheumatoid arthritis and psoriasis patients should be thoroughly evaluated for malignancies before and during treatment.
- Skin malignancies: Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Neoral. Malignant lesions may be hidden by psoriatic plaques. Biopsy skin lesions not typical of psoriasis before starting treatment. Treat with Neoral only after complete resolution of suspicious lesions, and only if there are no other treatment options.
- Serious infections: Patients receiving immunosuppressants, including Neoral, are at increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. Because of the danger of oversuppression of the immune system resulting in increased risk of infection or malignancy, a treatment regimen containing multiple immunosuppressants should be used with caution.
- Polyoma virus infections: Polyoma virus infections in transplant patients may have serious, and sometimes, fatal outcomes. Cases of JC virus-associated progressive multifocal leukoencephalopathy (PML) and polyoma virus-associated nephropathy (PVAN), especially due to BK virus infection, have been observed in patients receiving cyclosporine. Reducing total immunosuppression should be considered in transplant patients who develop PML or PVAN, although it may place the graft at risk.
- Neurotoxicity: There have been reports of convulsions in adult and pediatric patients receiving cyclosporine, particularly in combination with high dose methylprednisolone. Encephalopathy, including Posterior Reversible Encephalopathy Syndrome (PRES), has been described, with impaired consciousness, convulsions, visual disturbances (including blindness), loss of motor function, movement disorders and psychiatric disturbances. The changes in most cases have been reversible upon discontinuation of cyclosporine.
- Optic disc edema: Another rare manifestation of cyclosporine-induced neurotoxicity, occurring in transplant patients more frequently than in other indications, is optic disc edema including papilledema, with possible visual impairment, secondary to benign intracranial hypertension.
- Alcohol (ethanol): The alcohol content of Neoral should be taken into account when given to patients in whom alcohol intake should be avoided or minimized, such as pregnant or breastfeeding women, patients with liver disease or epilepsy, alcoholic patients, or pediatric patients. For an adult weighing 70 kg, the maximum daily oral dose would deliver about 1 gram of alcohol.
- Vaccination: During treatment with cyclosporine, vaccination may be less effective, and the use of live attenuated vaccines should be avoided.
Common Side Effects
In kidney, liver, and heart transplantation, the principal adverse reactions of cyclosporine therapy are renal dysfunction, tremor, hirsutism, hypertension, and gum hyperplasia. Hypertension, which is usually mild to moderate, may occur in approximately 50% of patients following renal transplantation and in most cardiac transplant patients. In rheumatoid arthritis, the principal adverse reactions are renal dysfunction, hypertension, headache, gastrointestinal disturbances, and hirsutism/hypertrichosis. In psoriasis, the principal adverse reactions are renal dysfunction, headache, hypertension, hypertriglyceridemia, hirsutism/hypertrichosis, paresthesia or hyperesthesia, influenza-like symptoms, nausea/vomiting, diarrhea, abdominal discomfort, lethargy, and musculoskeletal or joint pain.
Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to cyclosporine, including Neoral, during pregnancy. Available data over decades of use have not identified a drug associated risk of major birth defects, or miscarriage. Adverse maternal or fetal outcomes including hypertension, preeclampsia, preterm birth, and low birth weight are increased in patients treated with cyclosporine, although patients receiving cyclosporine during pregnancy have underlying medical conditions and may be treated with concomitant medications that limit the interpretability of these findings. Studies in rats and rabbits have shown embryo-fetal toxicity at dose levels below the maximum recommended human dose (MRHD) based on body surface area (BSA). The alcohol content of Neoral should be taken into account when given to pregnant women.
Lactation: Cyclosporine and its metabolites are present in human milk following oral and intravenous administration. Adverse effects on the breastfed infant have not been reported. There are no data on the effects of the drug on milk production. The alcohol content of Neoral should be taken into account when given to lactating women, and lactating women are encouraged to avoid additional alcohol intake during treatment.
Although no adequate and well-controlled studies have been completed in children, transplant recipients as young as one year of age have received Neoral with no unusual adverse effects. The safety and efficacy of Neoral treatment in children with juvenile rheumatoid arthritis or psoriasis below the age of 18 have not been established.